Isorhamnetin alleviates diet induced MASLD in mice by modulating gut microbiota and bile acid metabolism

Key Points

• Isorhamnetin significantly alleviates diet-induced MASLD in mice, enhancing gut microbiota diversity and bile acid metabolism.
• The treatment resulted in a notable decrease in MASLD markers, with liver fat reduced by over 30%.
• Observational analysis across various cohorts of mice highlighted significant microbiota shifts alongside metabolic improvements.
• These findings indicate that isorhamnetin may offer a potential dietary intervention, although further studies in humans are needed.